舒利迭治疗支气管哮喘的临床观察

The curative effect of seretide accuhaler on 86 patients with bronchial asthma

目的观察舒利迭(沙美特罗/丙酸氟替卡松)吸入剂治疗支气管哮喘的疗效。方法86例确诊为支气管哮喘的患者给予舒利迭(50/100ug或50/250ug),1吸/次,每日两次,经准纳器吸入,共用12周,观察治疗前后临床症状变化、药物不良反应、血清ET-1和IL-10水平以及肺功能(第一秒用力呼气容积、呼气峰流量)等变化情况。结果舒利迭治疗支气管哮喘良好以上控制率达到79.1%,治疗后血清ET-1水平(37.9±7.5)ng/L明显低于治疗前(76.2±8.1)ng/L,而血清IL-10水平(16.2±5.7)pg/ml则明显高于治疗前(11.3±3.8)pg/ml,肺功能较治疗前明显改善,FEV1和PEF分别由治疗前的1.82±0.42L、269±31L/min提高到3.09±0.59L、418±56L/min,具有统计学意义(P<0.01)。结论舒利迭是治疗支气管哮喘较理想的药物,值得推广使用。

Objective To observe the curative effect of seretide aceuhaler on bronchial asthma. Methods 86 patients with bronchial asthma were treated with seretide aecuhaler by accuhaler/diskus twice a day for 12 weeks, and the observayions were made on the change of the clinical symptom, undesirable effects and pulmonary function before and after inhale. Results The total effective rate of seretide accuhaler on bronchial asthma was 79. 1%. The serum levels of ET-1 and IL-10 in the treatment before and after the inhale were （76. 2 ± 8.1 ） ng/L, （37.9 ± 7.5 ） ng/L and （ 11.3 ±3.8 ） pg/ml, （ 16.2 ± 5.7 ） pg/ml, respectively. The pulmonary function was improved, and there was statistical difference between before and after the treatment. （P 〈 0.01 ）. Conclusion Seretide accuhaler has better clinical curative effect on bronchial asthma.